ZA202210224B - Chelator compositions for radiometals and methods of using same - Google Patents

Chelator compositions for radiometals and methods of using same

Info

Publication number
ZA202210224B
ZA202210224B ZA2022/10224A ZA202210224A ZA202210224B ZA 202210224 B ZA202210224 B ZA 202210224B ZA 2022/10224 A ZA2022/10224 A ZA 2022/10224A ZA 202210224 A ZA202210224 A ZA 202210224A ZA 202210224 B ZA202210224 B ZA 202210224B
Authority
ZA
South Africa
Prior art keywords
radiometals
methods
same
chelator compositions
chelator
Prior art date
Application number
ZA2022/10224A
Other languages
English (en)
Inventor
Hua Yang
Feng Gao
Paul Schaffer
Zheliang Yuan
Chengcheng Zhang
Francois Benard
Luke Wharton
Original Assignee
Triumf Inc
Provincial Health Services Authority
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Triumf Inc, Provincial Health Services Authority, Univ British Columbia filed Critical Triumf Inc
Publication of ZA202210224B publication Critical patent/ZA202210224B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/086—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being alphaMSH, alpha melanocyte stimulating hormone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Peptides Or Proteins (AREA)
ZA2022/10224A 2020-02-25 2022-09-14 Chelator compositions for radiometals and methods of using same ZA202210224B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062981113P 2020-02-25 2020-02-25
US202062993636P 2020-03-23 2020-03-23
PCT/CA2021/050226 WO2021168567A1 (en) 2020-02-25 2021-02-25 Chelator compositions for radiometals and methods of using same

Publications (1)

Publication Number Publication Date
ZA202210224B true ZA202210224B (en) 2023-04-26

Family

ID=77490568

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/10224A ZA202210224B (en) 2020-02-25 2022-09-14 Chelator compositions for radiometals and methods of using same

Country Status (7)

Country Link
US (1) US20230270892A1 (enExample)
EP (1) EP4110768A4 (enExample)
JP (1) JP2023514784A (enExample)
AU (1) AU2021226147A1 (enExample)
CA (1) CA3172811A1 (enExample)
WO (1) WO2021168567A1 (enExample)
ZA (1) ZA202210224B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
CA3136979A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
WO2022082312A1 (en) 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
CN114807636B (zh) * 2021-12-31 2023-10-20 中国工程物理研究院核物理与化学研究所 一种无载体177Lu和161Tb的GMP生产方法
KR20240167790A (ko) * 2022-03-30 2024-11-28 니혼 메디피직스 가부시키가이샤 복합체의 제조 방법
CN119325393A (zh) * 2022-05-03 2025-01-17 北卡罗来纳大学教堂山分校 用于成像和治疗应用的靶向ntsr的试剂的开发
CN115286697B (zh) * 2022-09-29 2022-12-13 烟台蓝纳成生物技术有限公司 一种双重靶向化合物及其制备方法和应用
WO2024235273A1 (zh) * 2023-05-15 2024-11-21 成都社泰医疗科技有限公司 多靶向化合物及其应用
AU2024346916A1 (en) * 2023-09-22 2026-03-26 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
WO2025156030A1 (en) * 2024-01-25 2025-07-31 The University Of British Columbia 1,7,13-trioxa-4,10,16-triazacyclooctadecane chelator compositions for radiometals and methods of using same
WO2025171492A1 (en) * 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
WO2025194281A1 (en) * 2024-03-22 2025-09-25 Triumf Inc. Chelator compositions for radiometals and methods of using same
CN118725025A (zh) * 2024-06-04 2024-10-01 厦门稀土材料研究所 用于177Lu标记的三齿类酰胺酸型双功能螯合剂及其制备方法和应用
WO2026000067A1 (en) * 2024-06-24 2026-01-02 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
WO2026096892A1 (en) * 2024-11-01 2026-05-07 Ratio Therapeutics, Inc. Somatostatin binding compositions and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517814B2 (en) * 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
CN102212042A (zh) * 2011-04-18 2011-10-12 北京师范大学 一种四氮杂冠醚的合成方法
CN104151367B (zh) * 2014-08-06 2016-05-04 北京师范大学 一种稀土镧配合物及其合成方法
CN104151368B (zh) * 2014-08-06 2016-05-04 北京师范大学 一种稀土铕配合物及其合成方法
CA3100868A1 (en) * 2018-05-23 2019-11-28 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy

Also Published As

Publication number Publication date
US20230270892A1 (en) 2023-08-31
AU2021226147A1 (en) 2022-09-22
JP2023514784A (ja) 2023-04-10
CA3172811A1 (en) 2021-09-02
EP4110768A1 (en) 2023-01-04
WO2021168567A1 (en) 2021-09-02
EP4110768A4 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
IL308155A (en) Crystalline forms of 5-fluoro-4-imino-3-methyl-1-tosyl-4,3-dihydropyrimidin-2-one and mixtures, compositions and methods of using them
SMT202500208T1 (it) Composizioni anticorpali e metodi per il loro uso
IL310530A (en) Stabilized compositions of radionuclides and their uses
IL279586A (en) Methods and preparations for the inhibition of dihydrourotate dehydrogenase
IL309952A (en) Compositions and methods for treating melanoma
EP4110768A4 (en) CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USE THEREOF
IL289649A (en) Formulations of rbp4 inhibitors and methods of use
IL315862A (en) Angiotensinogen modulators and methods of using them
EP4448514A4 (en) TYK2 INHIBITORS AND ASSOCIATED COMPOSITIONS AND PROCESSES
GB202015368D0 (en) Composition for the removal of stains and malodour
GB2622995B (en) CAS13-based compositions and methods of use thereof
IL287797A (en) Oligosaccharide preparations and methods of use
GB2627684B (en) Compositions and methods for well cementing
GB202408218D0 (en) Compositions and methods for well cementing
EP4415690A4 (en) COMPOSITIONS AND PROCEDURES FOR THE DISPENSING OF FUNDS
GB2613900B (en) Novel compounds and methods of use thereof
IL304159A (en) A preparation containing bl-8040
GB202408211D0 (en) Compositions and methods for well cementing
IL316049A (en) Musuntuzumab pharmaceutical preparations and methods of use
IL325816A (en) Endoxifen compositions and methods of use thereof and synthesis thereof
IL319844A (en) Compounds and compositions useful as IAPS inhibitors
IL327099A (en) Compounds and preparations as SPPL2A inhibitors
EP4054514A4 (en) COMPOSITIONS CONTAINING FENCHOLES AND METHOD OF USE
IL311518A (en) Preparations that modulate perkalkerine and methods of using them
IL304753A (en) Fertilizer compositions and their uses